DepoCyt (Chiron, Elan, Nippon-Shinyaku)

• Only FDA drug approvedfor neoplastic meningitis

  • Complication of cancer
  • Largely untreatedpatient population
  • Orphan drug status

• Global market sizeestimate: > $100 M

• US re-launch by Chiron

• EC marketing approval

Previous slide

Next slide

Back to first slide

View graphic version